Edgar Filing: MYRIAD GENETICS INC - Form 4

MYRIAD O Form 4 February 16	GENETICS INC 5, 2006									
FORM	ЛЛ							PPROVAL		
	UNITED		SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549			N OMB Number:	3235-0287			
Check t if no lor subject Section	nger STATEN to 16.	MENT OF CHA	F CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES					January 31, 2005 average urs per		
Form 5 obligati may con	obligations may continue. See InstructionSection 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940									
(Print or Type	Responses)									
	Address of Reporting IELD GREGORY	C Symbo	2. Issuer Name and Ticker or Trading Symbol MYRIAD GENETICS INC [MYGN]			5. Relationship of Reporting Person(s) to Issuer[]				
(Last)	(First) (Middle) 3. Date	of Earliest T	Transaction		(Che	eck all applicabl	e)		
320 WAKARA WAY			(Month/Day/Year) 02/16/2006			Director 10% Owner X_ Officer (give title Other (specify below) below) President Myriad Genetic Labs				
	(Street)	4. If A	4. If Amendment, Date Original			6. Individual or Joint/Group Filing(Check				
Filed(Month/Day/Year) SALT LAKE CITY, UT 84108						Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(State)	(Zip) Ta	able I - Non-	Derivative	Securities A	cquired, Disposed o	of, or Beneficia	lly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr. 8)	4. Securit onAcquired Disposed (Instr. 3, 4 Amount	(A) or of (D)	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Reminder: Re	port on a separate line	e for each class of so	ecurities bene	-	-	or indirectly.	ction of	SEC 1474		
								(0, 0, 0)		

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02) required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amour
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securit
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

Edgar Filing: MYRIAD GENETICS INC - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr. 8)	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	f			
				Code V	(A) (E) Date Exercisable	Expiration Date	Title	Amo or Num of Sh
Incentive Stock Option (right to buy)	\$ 24.4	02/16/2006		А	4,098	(1)	02/16/2016	Common Stock	4,0
Non-Qualified Stock Option (right to buy)	\$ 24.4	02/16/2006		А	27,902	(1)	02/16/2016	Common Stock	27,9

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	irector 10% Owner Officer					
CRITCHFIELD GREGORY C 320 WAKARA WAY SALT LAKE CITY, UT 84108			President Myriad Genetic Labs				

Signatures

By: Richard M. Marsh For: Gregory C. Critchfield

**Signature of Reporting Person

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The combined Incentive Stock Option and Non-Qualified Stock Option grants vest 25% annually beginning on the first anniversary date of the option grant, subject to statutory ISO limitations.

02/16/2006

Date

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.